Yesterday at the open we gapped up a few cents however the evening before in the after hours the stock traded higher after the close. Does yesterdays open still count as a gap up ? Ryman or someone else may be able to help me with an answer.
The only people making money with this company are the people that work there. For years investors have been stripped of their investment value by repeated delution and failure of the management to get this company to break even. The next catalyst is always a few months away but that catalyst never seems to change the overall finances of the company. If I ran my business like this company I would be broke. They need to get it together and return equity to shareholders now, not years from now.
If Otrexup sales continue to grow at the current 9% per quarter rate, break even for Otrexup should occur in Q1 2017 which is a few years later than expected. Last year we were told that a near term catalyst was injector sales increase to Ferring for 2 dosages of growth hormone. It looks like that only amounted to a 200k increase in revenue over last year from Ferring. If thats the case I would hardly call that a catalyst. They tout these products but they never seem to make any serious money from them and until that happens we will be hanging in dollar land.
They made it sound like the changes they put in place to impact Otrexup sales were not in place for the full second quarter and thats not true, most have been in place since 2015 with exception of the new dosages. They blame every negative number on the termination of the LEO partnership but its funny they never put enough effort into finding a partner which would have taken care of that issue for investors. Otrexup has been the one product with the potential of bringing the company to break even but they never put the effort into it that it deserves. Will Suma sales in Q4 result in profitability ? Will a QST partnership be announced in Q4 after NDA submission ?
You are correct they need to evaluate and communicate with investors regarding progress. When I called them in mid October regarding Otrexup sales, They told me all the changes they put into place were really starting to take effect,,, that apparently was not the case according to Q1 numbers. Also, Zomacton was said to be a catalyst last summer and fall with a fall 2016 launch but we have not received any updates on how many injectors were sold etc. Dont you think that information should be shared with investors ? They talk about future catalysts but once those catalyst hit the market we are left in the dark.
They failed to put enough effort into marketing Otrexup which could have made the company profitable by now. After LEO bailed out on the psoriasis deal Antares failed to find another partner. Psoriasis is only 10% of the total Otrexup market but its 10% we could use right now. I can remember the company saying that Otrexup would sell itself. It probably will but not to its full potential. They claimed it would be a 200 million market but we cant even currently break 20 million. We will have R & D revenue for the next few quarters and hopefully a smooth Suma launch. it will be interesting see what the Otrexup sales numbers have done for the last quarter. They claim to have put all these growth strategies in place... time will tell.
Well said Loko. It seems odd that 5 million short shares can cover yet the SP does not move. You or I cant buy 100 shares without it jumping up a penny. ATRS never takes advantage of opportunities to share investor info such as progress on products or new opportunities. Of course right now is a quiet time so they cant say anything until earnings I believe. Teva did get approval from the FDA yesterday for the Allergen merger deal. That deal should eventually result in opportunites for Antares injector platform but maybe not. Why the low, low volume lately ? Is that because the 5 million less short shares trading the penny back and forth ? This stock has been the worst investment of my life. If I ran my business like they run this company I would be broke, pathetic at best.
Apcodoc, what did I say that was a lie ? the quotes I used were directly from my notes of previous earnings and investor conferences. I didnt make anything up. I have been here since this company went by the ticker AIS. I am long the stock but dissappointed with management. Teva just had a presentation last week, not sure if that was what you are referring to. They did not mention EPI
I'm here because they have my retirement savings and I wont sell at a loss. I have to ride this out until they finally follow through and make the company profitable. 2014 was going to be the" break out year", 2015 was going to be a "very exciting year for all of us", and most recently they said "I am confident 2016 will be a very successful year". They have diluted the stock time after time, robbing shareholder value. The pipeline has potential but the only ones making money off this company in the past few years are the executives and the shorts.
Momma always told me if I don't have anything good to say... keep it to my self. Right now I don't have anything good to say. Hoping the company will show that they are looking out for the shareholders interest. If that happens, we will have something to talk about. Maybe they would like to tell us how Otrexup sales are doing by posting it on their website so investors could see it. They tell us how they put all these changes in place to boost sales but they never show us that what they have done is working.. When I called them last October they told me all the changes they put in place were really starting to take effect but months later the sales were still flat...
Unfortunately their presenter has a strong accent, its not easy to understand but I hope I can understand him when he mentions EPI...
Smart money knows something ? They always know before we do. What's ahead ?
I know it wasn't me because I wanted it to close above $4 The company needs to work on returning value to shareholders, its long overdue thats for sure. I hope they have a plan...
Where is the weatherguy, he is the one that says he knows how to read the technicals. Weatherguy, is there Sun in the forecast ?????
We are sitting pretty for a push up Nam. The RSI is 60 so we are not overbought, we could push higher and cross the 200 day, weeeeeeeeeeeeeeeee
Being in the top three Buy rating stocks should be an indicator that we are heading up. Technicals improving, naysayers are very quiet,,, time to move up. Nice steady upward move will force the shorts to buy in or risk losing the money they made off the short position.
Right, Antares sells to Teva in Q2, If Teva also sells those injectors in Q2, that revenue will come to ATRS in Q3. There isnt much time left in Q2 so we would be looking for Teva to sell in Q3 and that comes to ATRS in Q4. If anyone has access to Symphony numbers it would be nice to see where Otrexup sales are trending.
From what they said, they will sell pens to Teva in Q2 at cost until sold. There will be a 1Q delay in recording revenues.
Some were concerned about a cash raise but sumatriptan launch should settle those worries. Sumatriptan launch in addition to increasing development revenue during the last 3 Q's of 2016 will bring the company closer to profitability.